JP2018525383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525383A5 JP2018525383A5 JP2018506347A JP2018506347A JP2018525383A5 JP 2018525383 A5 JP2018525383 A5 JP 2018525383A5 JP 2018506347 A JP2018506347 A JP 2018506347A JP 2018506347 A JP2018506347 A JP 2018506347A JP 2018525383 A5 JP2018525383 A5 JP 2018525383A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- antibody
- protein
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562202366P | 2015-08-07 | 2015-08-07 | |
| US62/202,366 | 2015-08-07 | ||
| PCT/US2016/045535 WO2017027316A1 (en) | 2015-08-07 | 2016-08-04 | Anti-angptl8 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021034006A Division JP2021090449A (ja) | 2015-08-07 | 2021-03-04 | 抗−ａｎｇｐｔｌ８抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525383A JP2018525383A (ja) | 2018-09-06 |
| JP2018525383A5 true JP2018525383A5 (cg-RX-API-DMAC10.html) | 2019-09-05 |
| JP7141333B2 JP7141333B2 (ja) | 2022-09-22 |
Family
ID=56979626
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506347A Expired - Fee Related JP7141333B2 (ja) | 2015-08-07 | 2016-08-04 | 抗－ａｎｇｐｔｌ８抗体及びその使用 |
| JP2021034006A Pending JP2021090449A (ja) | 2015-08-07 | 2021-03-04 | 抗−ａｎｇｐｔｌ８抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021034006A Pending JP2021090449A (ja) | 2015-08-07 | 2021-03-04 | 抗−ａｎｇｐｔｌ８抗体及びその使用 |
Country Status (16)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| CA2954082A1 (en) * | 2014-10-03 | 2016-04-07 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| IL260931B2 (en) * | 2016-02-17 | 2024-09-01 | Regeneron Pharma | Methods of treating or preventing atherosclerosis by blocking ANGPTL3 |
| MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| PL3439689T3 (pl) * | 2016-04-08 | 2022-01-31 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3 |
| WO2018007999A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| CN110036029A (zh) | 2016-11-17 | 2019-07-19 | 瑞泽恩制药公司 | 用抗angptl8抗体处理肥胖的方法 |
| JP6853716B2 (ja) * | 2017-03-31 | 2021-03-31 | 信越化学工業株式会社 | レジスト下層膜材料、パターン形成方法、及びレジスト下層膜形成方法 |
| WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| WO2019006162A1 (en) | 2017-06-28 | 2019-01-03 | Bluefin Biomedicine, Inc. | ANTI-LY6H ANTIBODIES AND CONJUGATES ANTIBODY-MEDICINE |
| CN111315772A (zh) | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | 抗apoc3抗体及其使用方法 |
| EP3749691A4 (en) * | 2017-11-10 | 2021-10-27 | NGM Biopharmaceuticals, Inc. | ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE |
| WO2019126194A1 (en) * | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
| MX2021005048A (es) | 2018-10-31 | 2021-09-08 | Bioatla Inc | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. |
| TWI747098B (zh) | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| CA3131689A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| US11634501B2 (en) | 2019-07-19 | 2023-04-25 | Oncoresponse, Inc. | Immunomodulatory antibodies and methods of use thereof |
| CN110613847B (zh) * | 2019-10-23 | 2022-02-11 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110694068A (zh) * | 2019-11-06 | 2020-01-17 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110694067A (zh) * | 2019-11-06 | 2020-01-17 | 首都医科大学附属北京安贞医院 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN111135303A (zh) * | 2020-01-17 | 2020-05-12 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CA3190667A1 (en) | 2020-08-26 | 2022-03-03 | Aaron Sato | Methods and compositions relating to glp1r variants |
| US20250188154A1 (en) * | 2020-09-15 | 2025-06-12 | Duke University | Coronavirus antibodies and uses thereof |
| AU2023264772A1 (en) * | 2022-05-02 | 2024-10-24 | Novo Nordisk A/S | Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration |
| JP2025534874A (ja) * | 2022-09-30 | 2025-10-20 | ９１６３－０３８４ ケベック インコーポレイテッド | リポタンパク質リパーゼ欠損症及びリポタンパク質リパーゼの生物学的利用能の評価方法 |
| CN119192369A (zh) * | 2023-06-25 | 2024-12-27 | 百奥泰生物制药股份有限公司 | 抗angptl3抗体及其应用 |
| CN119684452B (zh) * | 2024-12-25 | 2026-03-27 | 中国药科大学 | Angptl8中和性抗体在制备治疗细胞因子风暴综合征药物中的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| US20020132252A1 (en) | 1997-06-16 | 2002-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7393663B2 (en) | 1997-08-01 | 2008-07-01 | Serono Genetics Institute S.A. | Expressed sequence tags and encoded human proteins |
| AU2577799A (en) | 1998-02-09 | 1999-08-23 | Human Genome Sciences, Inc. | 45 human secreted proteins |
| KR20050004240A (ko) | 1999-08-31 | 2005-01-12 | 제넨테크, 인크. | 종양 치료용 조성물 및 방법 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US7537903B2 (en) | 2007-04-23 | 2009-05-26 | Board Of Regents, The University Of Texas System | FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner |
| BRPI0812384A2 (pt) | 2007-05-22 | 2014-12-02 | Novartis Ag | Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21 |
| MX2012006397A (es) * | 2009-12-02 | 2012-11-30 | Amgen Inc | PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA. |
| JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
| US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| CN104039357A (zh) * | 2011-06-10 | 2014-09-10 | 哈佛学院校长同事会 | 胰腺β-细胞增殖的调节 |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| WO2013106547A1 (en) * | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| US20140178988A1 (en) * | 2012-10-08 | 2014-06-26 | Biotime, Inc. | Differentiated Progeny of Clonal Progenitor Cell Lines |
| WO2014183207A1 (en) * | 2013-05-17 | 2014-11-20 | Exerkine Corporation | Therapeutic method of treating metabolic syndrome |
| CN104164451A (zh) * | 2014-08-09 | 2014-11-26 | 高连如 | 一种治疗2型糖尿病的基因工程干细胞 |
| CA2954082A1 (en) * | 2014-10-03 | 2016-04-07 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| PL3439689T3 (pl) | 2016-04-08 | 2022-01-31 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3 |
| CN110036029A (zh) | 2016-11-17 | 2019-07-19 | 瑞泽恩制药公司 | 用抗angptl8抗体处理肥胖的方法 |
-
2016
- 2016-07-29 TW TW105124009A patent/TW201713690A/zh unknown
- 2016-08-04 EA EA201890453A patent/EA035088B1/ru not_active IP Right Cessation
- 2016-08-04 US US15/228,398 patent/US10259870B2/en active Active
- 2016-08-04 JP JP2018506347A patent/JP7141333B2/ja not_active Expired - Fee Related
- 2016-08-04 CA CA2993976A patent/CA2993976A1/en not_active Abandoned
- 2016-08-04 HK HK18109700.2A patent/HK1250238A1/zh unknown
- 2016-08-04 MX MX2018001532A patent/MX394103B/es unknown
- 2016-08-04 KR KR1020187006505A patent/KR20180038020A/ko not_active Withdrawn
- 2016-08-04 ES ES16770103T patent/ES2870031T3/es active Active
- 2016-08-04 CN CN201680046225.8A patent/CN107922478A/zh active Pending
- 2016-08-04 WO PCT/US2016/045535 patent/WO2017027316A1/en not_active Ceased
- 2016-08-04 AU AU2016307430A patent/AU2016307430B2/en not_active Ceased
- 2016-08-04 AR ARP160102386A patent/AR105600A1/es unknown
- 2016-08-04 EP EP16770103.6A patent/EP3331908B1/en active Active
-
2018
- 2018-01-18 ZA ZA2018/00352A patent/ZA201800352B/en unknown
- 2018-01-31 IL IL257263A patent/IL257263A/en unknown
-
2021
- 2021-03-04 JP JP2021034006A patent/JP2021090449A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cornell | A review of GLP‐1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once‐weekly agents | |
| JP2020522544A5 (cg-RX-API-DMAC10.html) | ||
| JP2023071827A5 (cg-RX-API-DMAC10.html) | ||
| US6939853B2 (en) | Combined use of a GLP-1 compound and another drug for treating dyslipidemia | |
| AU2023201872B2 (en) | Combinations of linagliptin and metformin | |
| US20190031774A1 (en) | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor | |
| CN101505594A (zh) | 代谢紊乱的组合治疗 | |
| Lau et al. | Impact of current and emerging glucose-lowering drugs on body weight in type 2 diabetes | |
| IL271212B2 (en) | Methods for treating hyperlipidemia in diabetic patients by administering a PCSK9 inhibitor | |
| JP2014504597A (ja) | アシル化グルカゴン類似体とインスリン類似体の組合せ物 | |
| Xie et al. | Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases | |
| JP2017522316A5 (cg-RX-API-DMAC10.html) | ||
| JP2018504111A (ja) | ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途 | |
| CA3103992A1 (en) | Cardiosafe antidiabetic therapy | |
| Gallwitz | Novel therapeutic approaches in diabetes | |
| JP2020500852A5 (cg-RX-API-DMAC10.html) | ||
| JP2005515214A5 (cg-RX-API-DMAC10.html) | ||
| Varin et al. | Glucagon-like peptide-1 receptor agonists in adult patients with type 2 diabetes: review of cardiovascular outcome trials | |
| FI4294257T3 (fi) | Menetelmä osittaisen lipodystrofian diagnosoimiseksi ja hoitamiseksi | |
| JP2015528460A (ja) | インクレチンホルモン又はそのアナログを用いた変形性関節症の処置 | |
| CN113631181A (zh) | 度拉糖肽的治疗用途 | |
| Gorecka et al. | Biological and biosimilar medicines in contemporary pharmacotherapy for metabolic syndrome | |
| CN114980916A (zh) | 用于2型糖尿病的长效glp1类似物药物 | |
| CA3150682A1 (en) | TREATMENT OF DIABETES SUGAR TYPE 2 | |
| RU2772712C2 (ru) | Способы лечения гиперлипидемии у пациентов с диабетом посредством введения ингибитора pcsk9 |